Drug intelligence / Profile preview

GB-NCS-1

Development stage: Preclinical
Lead developer: GlycosBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

GB-NCS-1 is a lipid-engineered nutraceutical candidate developed by GlycosBio, utilizing its proprietary Activated Oil System technology. Designed for oral administration, the product is intended to provide nutritional support for a healthy pregnancy by improving the bioavailability and delivery of essential lipids. Unlike traditional molecular-targeted pharmaceuticals, GB-NCS-1 focuses on lipid engineering to optimize nutritional uptake and support maternal and fetal health. It is currently in the clinical stage of development within GlycosBio's nutrition-focused pipeline.

Beyond the preview

Go deeper on GB-NCS-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-NCS-1.

Explore the full profile